Eyepoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at Guggenheim

Guggenheim assumed coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research report released on Thursday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $4.00 price objective on the stock.

EYPT has been the subject of a number of other research reports. HC Wainwright set a $5.00 price objective on Eyepoint Pharmaceuticals and gave the company a buy rating in a research note on Friday, July 12th. Zacks Investment Research lowered Eyepoint Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $4.13.

Shares of NASDAQ EYPT traded up $0.07 during trading on Thursday, reaching $1.87. 926,263 shares of the company traded hands, compared to its average volume of 392,581. The firm’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.73. The stock has a market cap of $196.66 million, a P/E ratio of -3.22 and a beta of 1.71. Eyepoint Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $3.94. The company has a current ratio of 5.46, a quick ratio of 5.31 and a debt-to-equity ratio of 1.75.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02. The business had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.75 million. Eyepoint Pharmaceuticals had a negative return on equity of 165.24% and a negative net margin of 621.04%. As a group, research analysts expect that Eyepoint Pharmaceuticals will post -0.39 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $27,000. JPMorgan Chase & Co. acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $28,000. Wells Fargo & Company MN boosted its holdings in Eyepoint Pharmaceuticals by 90.0% in the 2nd quarter. Wells Fargo & Company MN now owns 96,945 shares of the company’s stock worth $159,000 after buying an additional 45,922 shares during the last quarter. Northern Trust Corp boosted its holdings in Eyepoint Pharmaceuticals by 44.9% in the 2nd quarter. Northern Trust Corp now owns 167,434 shares of the company’s stock worth $275,000 after buying an additional 51,919 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Eyepoint Pharmaceuticals by 225.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 149,870 shares of the company’s stock worth $245,000 after buying an additional 103,857 shares during the last quarter. Hedge funds and other institutional investors own 58.62% of the company’s stock.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Read More: Trading signals using Bollinger bands

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit